PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(02): 151-155
DOI: 10.4103/sajc.sajc_125_18
Original Article

Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

M. Singhal
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi
,
T. P. Sahoo
Department of Medical Oncology, Chirayu Cancer Hospital, Bhopal, Madhya Pradesh
,
S. Aggarwal
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
,
A. Singhvi
Department of Medical Oncology, Choitram Hospital, Indore, Madhya Pradesh
,
V. Kaushal
Department of Radiation Oncology, RCC, Rohtak, Haryana
,
S. Rajpurohit
Department of Medical Oncology, RGCI, New Delhi
,
K. M. Parthasarthi
Department of Medical Oncology, Dharamshila Cancer Hospital, New Delhi
,
A. Vora
Department of Medical Oncology, Hope Clinic, New Delhi
,
M. Ganvir
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
,
S. Gupta
Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra
,
Purvish M. Parikh
Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra
› Author Affiliations
Financial support and sponsorship Nil.
› Further Information
Also available ateRef
 PDF Download Permissions and Reprints
Preview

Abstract

Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist with ovarian suppression plus multiple adjuvant therapy which provides a new treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

Key words

AI - exemestane - LHRH agonist - menopausal status - monitoring - tamoxifen


Publication History

Article published online:
22 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
  • 2 Goldhirsch A, Gelber RD. Breast cancer in young women. In: Harris JR, Lippman ME, Morrow M, editors. Diseases of the Breast. 3rd ed. Baltimore, MD: Lippincott Williams & Wilkins; 2004. p. 1339-49.
  • 3 Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am 1998;27:989-1006.
  • 4 Morimoto T, Okazaki M, Endo T. Current status and goals of mammographic screening for breast cancer in japan. Breast Cancer 2004;11:73-81.
  • 5 Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
  • 6 Paterson R, Russel MH. Clinical trials in malignant disease. Part II-breast cancer: Value of irradiation of the ovaries. J Fac Radiol 1959;10:130-3.
  • 7 Ovarian ablation in early breast cancer: Overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996;348:1189-96.
  • 8 Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/Ethnicity, poverty, and state. J Natl Cancer Inst 2015;107:djv048.
  • 9 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
  • 10 Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
  • 11 Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372:436-46.
  • 12 Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18.
  • 13 National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In: Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR); 2006. p. 8-30.
  • 14 Badwe RA, Gangawal S, Mittra I, Desai PB. Clinico-pathological features and prognosis of breast cancer in different religious communities in India. Indian J Cancer 1990;27:220-8.
  • 15 Altekruse SF, Kosary CL, Krapcho M, editors. In: SEER Cancer Statistics Review. National Cancer Institute; 1975-2007.
  • 16 National Cancer Registry Program. Ten Year Consolidated Report of the Hospital Based Cancer Registries, 1984–1993, an Assessment of the Burden and Care of Cancer Patients. New Delhi: Indian Council of Medical Research; 2001.
  • 17 Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007;31:1031-40.
  • 18 Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr. Deshler A, et al. National institutes of health consensus development conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
  • 19 Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:3817-27.
  • 20 LHRH-agonists in Early Breast Cancer Overview Group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23.
  • 21 Griggs JJ, Somerfield MR, Anderson H, Henry NL, Hudis CA, Khatcheressian JL, et al. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol 2011;29:3939-42. In Erratum, J Clin Oncol 2012;30:1398.
  • 22 Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) trial VI. Eur J Cancer 1998;34:632-40.
  • 23 International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group trial 13-93. J Clin Oncol 2006;24:1332-41.
  • 24 Swain SM, Jeong JH, Wolmark N. Amenorrhea from breast cancer therapy – not a matter of dose. N Engl J Med 2010;363:2268-70.
  • 25 Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr., et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast 2014;23:209-20.
  • 26 Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. Breast 2013;22:1094-100.
  • 27 Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2003;21:1836-44.
  • 28 Berglund G, Nystedt M, Bolund C, Sjödén PO, Rutquist LE. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2001;19:2788-96.
  • 29 Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014;32:3948-58.
  • 30 Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
  • 31 Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
  • 32 Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
  • 33 Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
  • 34 Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
  • 35 Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment. Lancet 1896;2:104-7, 162-5.
  • 36 Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001;67-71.
  • 37 Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature. Int J Cancer 2004;112:357-64.
  • 38 Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, De Matteis A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 1994;5:337-42.
  • 39 Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 1998;16:994-9.
  • 40 Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975;292:117-22.
  • 41 Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
  • 42 Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001;93:112-20.
  • 43 Mehta RR, Beattie CW, Das Gupta TK. Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 1992;20:125-32.
  • 44 Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer – Another step forward. J Natl Cancer Inst 2003;95:1811-2.
  • 45 Brueggemeier RW. Aromatase inhibitors: New endocrine treatment of breast cancer. Semin Reprod Med 2004;22:31-43.
  • 46 Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90:590-4.
  • 47 International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer?First results of International Breast Cancer Study Group Trial 11-93. Breast 2001;10 Suppl 3:130-8.
  • 48 Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
  • 49 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-5.
  • 50 Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: Understanding the overview. International Breast Cancer Study Group. J Clin Oncol 1993;11:580-5.
  • 51 Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
  • 52 Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
  • 53 Nahta R, Esteva FJ. HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 2003;9:5078-84.
  • 54 Esteva FJ. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 2004;9 Suppl 3:4-9.
  • 55 Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents. Drugs 2000;59:753-67.